CSL Seqirus: We have an exciting opportunity available for Senior Scientist, Bioinformatics & Data science, to join our Biopharmaceutical Product Development (... Waltham, Massachusetts

CSL Seqirus: We have an exciting opportunity available for Senior Scientist, Bioinformatics & Data science, to join our Biopharmaceutical Product Development (B... Waltham, Massachusetts

Sandia National Laboratories: About Sandia Sandia National Laboratories is the nation's premier science and engineering lab for national security and technology innovation, with... Livermore, California, Working from home

InVitro Cell Research, LLC: We're hiring Bioinformatics Scientists with strong backgrounds in database development, management and analysis as they relate to human health and... Leonia, New Jersey

CSL: We have an exciting opportunity available for Senior Scientist, Bioinformatics & Data science, to join our Biopharmaceutical Product Development (B... Waltham, Massachusetts

InnerPlant: About Us InnerPlant is the place for curious people who want to create innovative traits that harness plant physiology and unlock data at scale to... Davis, California

Eli Lilly and Company: At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indian... Indianapolis, Indiana

Notice NOT-CA-24-056 from the NIH Guide for Grants and Contracts

Notice NOT-EY-24-007 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-25-011 from the NIH Guide for Grants and Contracts. This NOFO invites applications that propose the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias (ADRDs). This NOFO seeks to promote critical target validation approaches to help de-risk subsequent translational research and accelerate the advancement of novel therapies for ADRD. Target(s) or molecular pathway(s) to be considered for validation must have been already identified using tissue expression or genetic data generated in human samples. In its initial phase, this FOA provided support for up to two years (R61 stage) for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidate(s) in cells or tissues and monitor their functional biological consequences in in vitro or in vivo disease models. Upon demonstration of technical feasibilities, a second phase (R33 stage) will carefully and reproducibly measure and cross-validate the impact of the target modulation in different modalities across collaborating laboratories using the NIH rigor and reproducibility guidelines. Applicants responding to this NOFO must address objectives for both the R61 and R33 phases and are expected to have a substantial collaborative effort between independents laboratories. This NOFO is not specific for any one or group within the ADRD spectrum of disorders. Disorders covered in these applications are frontotemporal degeneration (FTD), Lewy body dementias (LBD) (including dementia with Lewy bodies (DLB)), Parkinson disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), mixed dementias including the associated diagnostic challenges of multiples etiology dementias (MED).

Notice NOT-DE-24-019 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-129 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-25-056 from the NIH Guide for Grants and Contracts. There is a lack of early translational funding and technical support for new product developers to move beyond the idea stage and into the product development space. Establishing a technical development center (or centers) will assist researchers developing new digital therapeutics for SUD. These centers will provide idea developers with technical development support to prepare the PI for future funding applications (e.g. Phase I SBIR, other NIH research grants, Blueprint Neurotherapeutics or Blueprint MedTech, etc.). The technical development assistance will include support from experts in the idea to product translation activities including the following: target product profile development clinical need assessment project plan development with timeline and milestones prototype development proof-of-concept study design preliminary safety assessments assistance in understanding current and future regulatory requirements

Funding Opportunity RFA-DC-24-008 from the NIH Guide for Grants and Contracts. NIDCD invites applications for formative dissemination and implementation (D and I) research projects in NIDCD mission areas of hearing, balance, taste, smell, voice, speech, and language.

Notice NOT-NS-24-077 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-018 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-012 from the NIH Guide for Grants and Contracts

Notice NOT-DA-24-032 from the NIH Guide for Grants and Contracts

Notice NOT-MD-24-018 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-050 from the NIH Guide for Grants and Contracts